Literature DB >> 17087734

Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair.

Agata A Zyrek1, Christoph Cichon, Simone Helms, Corinne Enders, Ulrich Sonnenborn, M Alexander Schmidt.   

Abstract

The probiotic Escherichia coli strain Nissle 1917 (EcN) has been used for decades in human medicine in Central Europe for the treatment and prevention of intestinal disorders and diseases. However, the molecular mechanisms underlying its beneficial effects are only partially understood. To identify molecular responses induced by EcN that might contribute to its probiotic properties polarized T84 cells were investigated employing DNA microarrays, quantitative RT-PCR, Western blotting, immunofluorescence and specific protein kinase C (PKC) inhibitors. Polarized T84 epithelial cell monolayers were used as a model to monitor barrier disruption by infection with the enteropathogenic E. coli (EPEC) strain E2348/69. Co-incubation of EPEC with EcN or addition of EcN following EPEC infection abolished barrier disruption and, moreover, restored barrier integrity as monitored by transepithelial resistance. DNA-microarray analysis of T84 cells incubated with EcN identified 300+ genes exhibiting altered expression. EcN altered the expression, distribution of zonula occludens-2 (ZO-2) protein and of distinct PKC isotypes. ZO-2 expression was enhanced in parallel to its redistribution towards the cell boundaries. This study provides evidence that EcN induces an overriding signalling effect leading to restoration of a disrupted epithelial barrier. This is transmitted via silencing of PKCzeta and the redistribution of ZO-2. We suggest that these properties contribute to the reported efficacy in the treatment of inflammatory bowel diseases and in part rationalize the probiotic nature of EcN.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17087734     DOI: 10.1111/j.1462-5822.2006.00836.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  133 in total

Review 1.  Regulation of intestinal epithelial permeability by tight junctions.

Authors:  Takuya Suzuki
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

Review 2.  Intestinal effect of the probiotic Escherichia coli strain Nissle 1917 and its OMV.

Authors:  Ava Behrouzi; Hoora Mazaheri; Sarvenaz Falsafi; Zahra Hoseini Tavassol; Arfa Moshiri; Seyed Davar Siadat
Journal:  J Diabetes Metab Disord       Date:  2020-05-01

3.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

Review 4.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 5.  Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.

Authors:  Franco Scaldaferri; Viviana Gerardi; Francesca Mangiola; Loris Riccardo Lopetuso; Marco Pizzoferrato; Valentina Petito; Alfredo Papa; Jovana Stojanovic; Andrea Poscia; Giovanni Cammarota; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

6.  How can probiotics and prebiotics impact mucosal immunity?

Authors:  Sarah O'Flaherty; Delphine M Saulnier; Bruno Pot; James Versalovic
Journal:  Gut Microbes       Date:  2010-07-07

7.  A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation.

Authors:  Rose A Whelan; Sebastian Rausch; Friederike Ebner; Dorothee Günzel; Jan F Richter; Nina A Hering; Jörg-Dieter Schulzke; Anja A Kühl; Ahmed Keles; Pawel Janczyk; Karsten Nöckler; Lothar H Wieler; Susanne Hartmann
Journal:  Mol Ther       Date:  2014-07-02       Impact factor: 11.454

8.  Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease.

Authors:  E Quévrain; M A Maubert; C Michon; H Sokol; P Seksik; F Chain; R Marquant; J Tailhades; S Miquel; L Carlier; L G Bermúdez-Humarán; B Pigneur; O Lequin; P Kharrat; G Thomas; D Rainteau; C Aubry; N Breyner; C Afonso; S Lavielle; J-P Grill; G Chassaing; J M Chatel; G Trugnan; R Xavier; P Langella
Journal:  Gut       Date:  2015-06-04       Impact factor: 23.059

Review 9.  Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.

Authors:  Giulia Paolella; Claudia Mandato; Luca Pierri; Marco Poeta; Martina Di Stasi; Pietro Vajro
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

10.  Probiotic bacteria influence the composition and function of the intestinal microbiota.

Authors:  Paul W O'Toole; Jakki C Cooney
Journal:  Interdiscip Perspect Infect Dis       Date:  2008-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.